4/A//SEC Filing
Quiroga Cortes Isidoro Alfonso 4/A
Accession 0001104659-22-115487
CIK 0001856725other
Filed
Nov 6, 7:00 PM ET
Accepted
Nov 7, 5:08 PM ET
Size
12.5 KB
Accession
0001104659-22-115487
Insider Transaction Report
Form 4/AAmended
Quiroga Cortes Isidoro Alfonso
10% Owner
Transactions
- Purchase
Class A Common Stock
2022-10-31$6.11/sh+16,523$100,977→ 5,218,821 total(indirect: By Partnership) - Purchase
Class A Common Stock
2022-11-01$5.98/sh+3,768$22,533→ 5,222,589 total(indirect: By Partnership) - Purchase
Class A Common Stock
2022-11-02$6.31/sh+25,197$158,955→ 5,247,786 total(indirect: By Partnership)
Aequanimitas Limited Partnership
10% Owner
Transactions
- Purchase
Class A Common Stock
2022-11-01$5.98/sh+3,768$22,533→ 5,222,589 total(indirect: By Partnership) - Purchase
Class A Common Stock
2022-10-31$6.11/sh+16,523$100,977→ 5,218,821 total(indirect: By Partnership) - Purchase
Class A Common Stock
2022-11-02$6.31/sh+25,197$158,955→ 5,247,786 total(indirect: By Partnership)
Footnotes (5)
- [F1]This amendment to Isidoro Alfonso Quiroga Cortes' Form 4, originally filed with the SEC on November 2, 2022 (the "Original Form 4"), is being filed to include Aequanimitas Limited Partnership ("Aequanimitas") as a Reporting Person under the Original Form 4.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.98 to $6.14 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.96 to $6.22 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.01 to $6.50 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- [F5]Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas as its general partner with the power to manage Aequanimitas. Isidoro Alfonso Quiroga Cortes is the sole limited partner of Aequanimitas.
Documents
Issuer
Rani Therapeutics Holdings, Inc.
CIK 0001856725
Entity typeother
Related Parties
1- filerCIK 0001854578
Filing Metadata
- Form type
- 4/A
- Filed
- Nov 6, 7:00 PM ET
- Accepted
- Nov 7, 5:08 PM ET
- Size
- 12.5 KB